Weihao Xu

Stealth mode biotech with top tier VC backing, focusing on autoimmune and inflammation diseases

- Closed more than 15 deals all the way from lead generation to closing, 10 publicly announced. More than $5 Billion total economic value to the company. - Turned company from a loss making into a profitable biotech. - Launched Nona Bioscience from scratch. Built out the entire marketing position and generated more than $10mil first year revenue. - Designed and expanded Harbour into two prone approach business with both therapeutics development and technology platform services. 1. HBM9033 Phase 1 ready MSLN-ADC global right outlicense to Seagen/Pfizer, USD $53 million upfront, $1.03 billion milestone plus tiered royalties. 2. HBM7022 pre-clinical bispecific global right outlicense to Astrazenca, USD $25 million upfront, $400 million milestone plus tiered royalties. 3. Preclinical mAb global right outlicense to Astrazenca, USD $19mil upfront, $10mil near term milestone, $400 million future milestone plus tiered royalties. 4. HBM7008 phase 1 bispecific US right outlicense to Cullinan Oncology, USD $25 million upfront, $600 million milestone plus tiered royalties. 5. HBM9161 phase 3 program China right outlicense to CSPC, RMB 150 million upfront, 1 billion milestone plus tierd royalties 6. Moderna partnership on several targets: USD $6 million upfront, $500 mil milestone 7. HBM Alpha seed round financing 8. Dragonfly partnership - undisclosed deal amount 9. Several ADC partnership: Kelun, DualityBio, Lego Chem 10. Disposal of CMC facility to WuXi biologics for 146 million RMB.

PM of Asia Growth Fund - a Pan-Asia growth strategy with $1.5bn AUM. Focus on internet and healthcare equity research and investment.

- Led the company’s Pre-IPO financing of $50 mil and Nasdaq IPO of $120 mil at $1.2bn market cap.

- Portfolio manager managing multiple portfolios investing in Emerging markets via public companies, private companies and hedge funds.

Global Long/short equity with a focus in Europe and Japan.